INCY

Business Context and Reporting Period

Company: Incyte Corporation (formerly Incyte Genomics, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2003
Business Overview: Incyte is a drug discovery company focused on therapeutic discovery and development (cancer, inflammatory diseases) and the licensing of genomic information and intellectual property. The company operates as a single segment.

Key Financial Metrics

Liquidity: As of March 31, 2003, the company held $376.2 million in cash, cash equivalents, and marketable securities. Net cash used in operating activities was $42.8 million.

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 57% to $12.5 million from $29.0 million. This reflects a softening market for genomic information, reduced R&D spending by pharmaceutical customers, and the exit of custom genomics product lines in 2001.
• Increased Net Loss: Net loss widened significantly to $55.8 million from $13.4 million. The primary driver was a one-time charge of $28.1 million for purchased in-process research and development (IPRD) related to the acquisition of Maxia Pharmaceuticals, Inc.
• Expense Reductions: Despite the acquisition charge, Research & Development expenses decreased to $30.2 million (from $33.7 million) and Selling, General & Administrative (SG&A) expenses dropped to $7.4 million (from $14.2 million) due to restructuring programs initiated in late 2002.
• Cash Position: Cash and cash equivalents decreased by $12.3 million during the quarter, primarily due to operating losses and capital expenditures, though investing activities provided net cash of $30.6 million due to the net sale of marketable securities.

Guidance, Outlook, and Risks

• Outlook: Management expects revenues in 2003 to be lower than in 2002 due to market softening. The company anticipates incurring additional losses for the next several years as it expands therapeutic discovery programs. It expects to reduce annual expenses by over $80 million in 2003 compared to 2002 through restructuring, though this will be partially offset by increased therapeutic R&D spending.
• Acquisition Impact: The acquisition of Maxia Pharmaceuticals (completed Feb 2003) added a pipeline of small molecule drugs. The purchase price was approximately $27.4 million, with $28.1 million expensed immediately as IPRD. Potential earn-out payments of up to $14.0 million may be required based on future milestones.
• Restructuring: The company continues to execute restructuring plans from 2001 and 2002, involving workforce reductions and facility consolidations. Additional charges of $1.1 million were recorded in Q1 2003 related to these plans.
• Risks:
  • Profitability: No expectation of profitability in the near term; significant capital required for drug development.
  • Debt: $171.9 million in convertible subordinated notes due in 2007 creates fixed charge obligations.
  • Intellectual Property: Ongoing patent litigation with Invitrogen Corporation; uncertainty regarding the enforceability of gene patents.
  • Market Dependence: Heavy reliance on pharmaceutical and biotechnology customers whose R&D budgets are subject to consolidation and economic pressures.

Investor Verification Checklist

• Maxia Acquisition Accounting: Verify the final purchase price allocation and the status of the $28.1 million IPRD charge.
• Restructuring Accruals: Monitor the utilization of the $19.8 million accrued restructuring liability and potential for additional charges related to lease commitments.
• Debt Service: Assess the ability to service $171.9 million in convertible notes given the current cash burn rate and lack of operating profitability.
• Patent Litigation: Track the status of the Invitrogen lawsuit and potential financial exposure or licensing requirements.
• Revenue Trends: Confirm if the decline in database subscription renewals and pricing pressure continues into subsequent quarters.